CAMP4 Therapeutics Appoints Michael MacLean to Board, Advances SYNGAP1 Program
CAMP4 Therapeutics appoints Michael MacLean to its Board of Directors as the company advances CMP-002 toward a Phase 1/2 trial for SYNGAP1-related disorder. The company also announced an inducement stock option grant of 8,000 shares at $3.85 per share to a new employee. CAMP4 is developing regulatory RNA-targeting therapeutics to upregulate gene expression for genetic diseases.
CAMP4 Therapeutics has appointed Michael MacLean to its Board of Directors as the company advances its lead program CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder. The appointment enhances strategic and financial leadership at the clinical-stage biopharmaceutical company, which is developing regulatory RNA-targeting therapeutics designed to upregulate gene expression to treat genetic diseases.
Michael MacLean brings more than 35 years of strategic financial leadership in the biotechnology and life sciences industries, with extensive experience supporting the growth of innovative biotechnology companies advancing novel genetic medicines. Most recently, he served as Chief Financial Officer at Avidity Biosciences, joining prior to the company's 2020 IPO and leading finance and business functions until its acquisition by Novartis in 2026. Prior to Avidity, he served as Chief Financial Officer and Executive Vice President of Akcea Therapeutics, where he led the buildout of the company's financial and commercial infrastructure.
The company's approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. Its therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4's proprietary RAP Platform enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200.
Separately, CAMP4 Therapeutics announced an inducement option grant on February 16, 2026 to a newly hired employee. The company granted a non-qualified stock option for 8,000 shares with a 10-year term and an exercise price of $3.85, equal to the closing price on the grant date. The option vests over four years: 25% on the first anniversary and the remainder in 36 equal monthly installments, subject to continued service, under an Inducement Option Award Agreement.
The company has an active S-3 shelf registration filed on November 10, 2025 that registers up to $300,000,000 of securities and includes an at-the-market component of up to $100,000,000. This follows recent strategic activity including a $30.0 million underwritten offering at $6.00 and a separate GSK collaboration with $17.5 million upfront and up to $440 million in milestones announced in December 2025.